---
schema_version: "secwatch.filing_event.v1"
accession: "0001323885-22-000008"
form_type: "8-K"
ticker: "ATRC"
cik: "0001323885"
company_name: "AtriCure, Inc."
filed_at: "2022-02-15T23:59:59+00:00"
generated_at: "2026-06-27T07:53:03.699995+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AtriCure Q4 revenue $73.2M (+26.8% YoY); guides FY22 rev $315-330M

## Summary
- Q4 2021 revenue $73.2M (+26.8% YoY); U.S. $61.2M (+29.1%), Intl $12.0M (+16.3%).
- FY2021 revenue $274.3M (+32.8%); GAAP net income $1.11/shr; adj loss per share $1.16.
- FY2021 includes $184.8M credit for contingent consideration change and $82.3M IPR&D impairment.
- FY2022 revenue guidance $315-330M (15-20% growth); adj EBITDA loss $2-4M; adj loss/shr $1.07-1.12.
- Milestones: Hybrid Therapy FDA approval, ENCOMPASS 510(k), Cryo Nerve Block expansion.

## SEC filing metadata
- accession: 0001323885-22-000008
- form_type: 8-K
- ticker: ATRC
- cik: 0001323885
- company_name: AtriCure, Inc.
- filed_at: 2022-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1323885/000132388522000008/0001323885-22-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1323885/000132388522000008/atrc-20220215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001323885-22-000008
- JSON: https://secwatch.observer/filing/0001323885-22-000008.json
- Plain text: https://secwatch.observer/filing/0001323885-22-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.